The global AI in pharma manufacturing market size is estimated to grow from USD 1.20 billion in the current year to USD 34.7 billion by 2040, at a CAGR of 28% during the forecast period, till 2040. The new study provides market size, growth scenarios, industry trends and future forecasts.
Artificial Intelligence (AI) is a subdivision of computer science that enables computers to perform intricate tasks that usually require human intelligence, including learning, reasoning, and making decisions. In the healthcare sector, AI is already being applied in various areas such as drug discovery, clinical trials, diagnostics, personalized medicine, and data management. Within pharmaceutical manufacturing, AI utilizes technologies like computer vision, machine learning, generative AI, and deep learning to improve process monitoring, identify inefficiencies, lower production costs, and enhance product yield.
Pharmaceutical manufacturing faces numerous inefficiencies, including inefficient workflows, equipment downtime, quality control issues, and supply chain interruptions. These inefficiencies can result in higher costs, production delays, and variability in product quality. AI addresses these challenges by enabling process optimization, monitoring the performance of plants and equipment, anticipating equipment failures beforehand, managing supply chains, and automating quality control processes. Several pharmaceutical companies, including Pfizer, Moderna, Novartis, Merck, and Sanofi, are integrating AI into their manufacturing operations as the sector evolves towards Pharma 4.0.
More than 60% of major pharmaceutical companies are utilizing AI to revolutionize their manufacturing processes, improving efficiency, quality, and flexibility. Prominent applications include real-time monitoring, automated quality inspections, predictive maintenance, and optimization of the supply chain.
For example, Sanofi applies AI to enhance production yield and process effectiveness; Novartis uses machine learning techniques for real-time monitoring of plants and AI-powered supply chain optimization in drug production; Merck utilizes AI to decrease false reject rates in quality assessments; and Moderna leverages AI-based tools to improve quality control systems. These technologies not only streamline processes but also lead to cost savings and a better regulatory environment for AI in the drug manufacturing sector.
As top pharmaceutical firms and AI solution providers continue to develop their capabilities, incorporating AI into drug manufacturing has become essential for achieving operational excellence and sustaining a competitive advantage in this swiftly changing industry.
It is worth noting that AI applications in drug manufacturing encompass a range of functions, including quality control, predictive maintenance, process development and optimization, monitoring of plant and equipment performance, as well as supply chain optimization. The broadening range of these applications continues to propel substantial market demand for AI solutions specifically designed for pharmaceutical manufacturing.
Importantly, over 95% of the companies involved in AI for drug production provide advanced software solutions. Further, nearly 80% of these firms are implementing machine learning to digitize various phases of the drug manufacturing process.
However, it is worth highlighting that the market in Asia-Pacific is expected to grow at a higher CAGR during the forecast period. This is driven by the lower implementation costs, supportive government policies fostering digitalization, and rapidly expanding pharmaceutical sector.
Artificial Intelligence (AI) is a subdivision of computer science that enables computers to perform intricate tasks that usually require human intelligence, including learning, reasoning, and making decisions. In the healthcare sector, AI is already being applied in various areas such as drug discovery, clinical trials, diagnostics, personalized medicine, and data management. Within pharmaceutical manufacturing, AI utilizes technologies like computer vision, machine learning, generative AI, and deep learning to improve process monitoring, identify inefficiencies, lower production costs, and enhance product yield.
Pharmaceutical manufacturing faces numerous inefficiencies, including inefficient workflows, equipment downtime, quality control issues, and supply chain interruptions. These inefficiencies can result in higher costs, production delays, and variability in product quality. AI addresses these challenges by enabling process optimization, monitoring the performance of plants and equipment, anticipating equipment failures beforehand, managing supply chains, and automating quality control processes. Several pharmaceutical companies, including Pfizer, Moderna, Novartis, Merck, and Sanofi, are integrating AI into their manufacturing operations as the sector evolves towards Pharma 4.0.
Strategic Insights for Senior Leaders
What are the Use Cases of Artificial Intelligence in Pharmaceutical Manufacturing?More than 60% of major pharmaceutical companies are utilizing AI to revolutionize their manufacturing processes, improving efficiency, quality, and flexibility. Prominent applications include real-time monitoring, automated quality inspections, predictive maintenance, and optimization of the supply chain.
For example, Sanofi applies AI to enhance production yield and process effectiveness; Novartis uses machine learning techniques for real-time monitoring of plants and AI-powered supply chain optimization in drug production; Merck utilizes AI to decrease false reject rates in quality assessments; and Moderna leverages AI-based tools to improve quality control systems. These technologies not only streamline processes but also lead to cost savings and a better regulatory environment for AI in the drug manufacturing sector.
As top pharmaceutical firms and AI solution providers continue to develop their capabilities, incorporating AI into drug manufacturing has become essential for achieving operational excellence and sustaining a competitive advantage in this swiftly changing industry.
Key Drivers Propelling Growth of AI in Pharma Manufacturing Market
The growth of AI in the drug manufacturing sector is driven by an increasing demand for enhanced process efficiency, lower production costs, and the maintenance of consistent product quality. Additionally, rising regulatory support and the ongoing digital transformation within the pharmaceutical industry further promotes the adoption of cutting-edge AI technologies.It is worth noting that AI applications in drug manufacturing encompass a range of functions, including quality control, predictive maintenance, process development and optimization, monitoring of plant and equipment performance, as well as supply chain optimization. The broadening range of these applications continues to propel substantial market demand for AI solutions specifically designed for pharmaceutical manufacturing.
AI in Pharma Manufacturing Market: Competitive Landscape of Companies in this Industry
The present market environment consists of approximately 130 participants, including major, large, medium, and small enterprises. These organizations possess the necessary skills to deliver AI solutions for drug production across various geographical areas.Importantly, over 95% of the companies involved in AI for drug production provide advanced software solutions. Further, nearly 80% of these firms are implementing machine learning to digitize various phases of the drug manufacturing process.
Regional Analysis: Asia-Pacific to Propel the market growth in the Coming Years
According to our projections, currently North America captures the majority of the market, and this trend is unlikely to change in the future as well. This is due to the presence of advanced pharma manufacturing infrastructure, early adoption of artificial intelligence (AI) in healthcare technologies and supportive regulatory framework across the region.However, it is worth highlighting that the market in Asia-Pacific is expected to grow at a higher CAGR during the forecast period. This is driven by the lower implementation costs, supportive government policies fostering digitalization, and rapidly expanding pharmaceutical sector.
AI in Pharma Manufacturing Evolution: Emerging Trends in the Industry
AI is transforming pharmaceutical manufacturing by making processes smarter, faster, and more reliable. Emerging trends include predictive maintenance using machine learning to spot equipment issues early, cutting downtime and costs. Real-time quality control with AI vision detects defects like cracks or contamination instantly in production lines, ensuring consistent drug quality and regulatory compliance. Process optimization employs advanced controls and digital twins to fine-tune parameters such as temperature and mixing, boosting efficiency and reducing waste. AI combined with robotics and IoT enables automated labs of the future for continuous monitoring and adaptive production. These innovations help pharma companies to produce safer medicines quicker while saving money and meeting strict standards.Key Market Challenges
The market for AI in pharma manufacturing faces significant challenges that slow its adoption. One of the primary challenges is data issues, with poor quality, biases, silos, and limited availability making AI models unreliable for precise production tasks. High costs for setup, integration with old systems, and ongoing maintenance strain budgets, especially for smaller firms hindering the adoption of such technologies. Additionally, strict regulations like GMP and FDA rules demand validation, transparency, and compliance, but AI's "black box" nature complicates approvals and ethics. Moreover, shortage of personnel skilled in both AI and pharmaceutical expertise hampers effective deployment of AI in the pharmaceutical manufacturing domain.AI in Pharma Manufacturing Market: Key Market Segmentation
Type of Offering
- Hardware
- Software
- Services
Mode of Deployment
- Cloud
- On-premise
Type of AI Solution
- Standard / Off-the-shelf AI solutions
- Personalized AI solutions
Type of Technology
- Computer Vision
- Deep Learning
- Generative AI
- Machine Learning
- Other Technologies
Application Area
- Process Development and Optimization
- Plant / Equipment Performance Monitoring
- Predictive Maintenance
- Quality Control
- Supply Chain Optimization
- Other Application Areas
Utility in Drug Manufacturing
- Defect Detection
- Packaging and Label Inspection
- Package Counting
- Fill Level Inspection
- Other Utilities
Geographical Regions
- North America
- US
- Canada
- Europe
- Germany
- UK
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Korea
- Australia
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East and North Africa
- Saudi Arabia
- UAE
- Egypt
- Rest of MENA
AI in Pharma Manufacturing Market: Key Market Share Insights
Market Share by Type of Offering
Based on the type of offering, the global market is segmented into hardware, software, and services. According to our estimates, currently, software captures majority share of the market. This is driven by the increasing adoption of software-based solutions that integrate advanced techniques, such as predictive analytics, and process optimization, thereby improving operational efficiency and foster innovation in drug manufacturing.Market Share by Type of AI Solution
Based on the type of AI solution, the global market is segmented into standard / off-the-shelf AI solutions and personalized AI solutions. According to our estimates, currently, standard / off-the-shelf AI solutions capture majority share of the market. This is primarily due to industry’s preference towards pre-validated, compliant, and ready-to-deploy solutions that can be deployed and scaled rapidly.AI in Pharma Manufacturing Market: Report Coverage
The report on the AI in pharma manufacturing market features insights on various sections, including:
- Market Sizing and Opportunity Analysis: An in-depth analysis of the AI in pharma manufacturing market, focusing on key market segments, including [A] type of offering, [B] mode of deployment, [C] type of AI solution, [D] type of technology, [E] application area, [F] utility in drug manufacturing, [G] geographical regions and [H] key players.
- Competitive Landscape: A comprehensive analysis of the companies engaged in the AI in pharma manufacturing market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters and [D] ownership structure.
- Company Profiles: Elaborate profiles of prominent players engaged in the AI in pharma manufacturing market, providing details on [A] location of headquarters, [B] company size, [C] company mission, [D] company footprint, [E] management team, [F] contact details, [G] financial information, [H] operating business segments, [I] portfolio, [J] recent developments, and an informed future outlook.
- Megatrends: An evaluation of ongoing megatrends in the AI in pharma manufacturing industry.
- Recent Developments: An overview of the recent developments made in the AI in pharma manufacturing market, along with analysis based on relevant parameters, including [A] year of initiative, [B] type of initiative, [C] geographical distribution and [D] most active players.
- SWOT Analysis: An insightful SWOT framework, highlighting the strengths, weaknesses, opportunities and threats in the domain. Additionally, it provides Harvey ball analysis, highlighting the relative impact of each SWOT parameter.
Key Questions Answered in this Report
- What is the current and future market size?
- Who are the leading companies in this market?
- What are the growth drivers that are likely to influence the evolution of this market?
- What are the key partnership and funding trends shaping this industry?
- Which region is likely to grow at higher CAGR till 2040?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- Detailed Market Analysis: The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- In-depth Analysis of Trends: Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. Each report maps ecosystem activity across partnerships, funding, and patent landscapes to reveal growth hotspots and white spaces in the industry.
- Opinion of Industry Experts: The report features extensive interviews and surveys with key opinion leaders and industry experts to validate market trends mentioned in the report.
- Decision-ready Deliverables: The report offers stakeholders with strategic frameworks (Porter’s Five Forces, value chain, SWOT), and complimentary Excel / slide packs with customization support.
Additional Benefits
- Complimentary Dynamic Excel Dashboards for Analytical Modules
- Exclusive 15% Free Content Customization
- Personalized Interactive Report Walkthrough with the Research Team
- Free Report Updates for Versions Older than 6-12 Months
Table of Contents
1. BACKGROUND
2. RESEARCH METHODOLOGY
3. MARKET DYNAMICS
4. MACRO-ECONOMIC INDICATORS
6. INTRODUCTION
7. MARKET LANDSCAPE: AI IN PHARMA MANUFACTURING SOLUTION PROVIDERS
8. COMPANY COMPETITIVENESS ANALYSIS
9. COMPANY PROFILES: AI IN PHARMA MANUFACTURING SOLUTION PROVIDERS IN NORTH AMERICA
10. COMPANY PROFILES: AI IN PHARMA MANUFACTURING SOLUTION PROVIDERS IN EUROPE
11. COMPANY PROFILES: AI IN PHARMA MANUFACTURING SOLUTION PROVIDERS IN ASIA-PACIFIC AND REST OF THE WORLD
12. PARTNERSHIPS AND COLLABORATIONS
13. FUNDING AND INVESTMENT ANALYSIS
14. START-UP HEALTH INDEXING
15. AI IN PHARMA MANUFACTURING MARKET: MEGATRENDS ANALYSIS
16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
17. GLOBAL AI IN PHARMA MANUFACTURING MARKET
18. AI IN PHARMA MANUFACTURING MARKET, BY TYPE OF OFFERING
19. AI IN PHARMA MANUFACTURING MARKET, BY MODE OF DEPLOYMENT
20. AI IN PHARMA MANUFACTURING MARKET, BY TYPE OF AI SOLUTION
21. AI IN PHARMA MANUFACTURING MARKET, BY TYPE OF TECHNOLOGY
22. AI IN PHARMA MANUFACTURING MARKET, BY APPLICATION AREA
23. AI IN PHARMA MANUFACTURING MARKET, BY UTILITY IN DRUG MANUFACTURING
24. AI IN PHARMA MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS
26. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
27. MARKET OPPORTUNITY ANALYSIS: EUROPE
28. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
29. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
• AMD
• IBM
• Kalypso
• SAS Institute
• Körber Pharma
• SDG Group
• Catalyx
• Elisa Industriq
• Straive
• Axiomtek
• Appinventiv
• Amplelogic
• Precognize
Methodology
LOADING...
